SCHEMBL5374285

SCHEMBL5374285

CC(C)(CC(O)(CO)CC1CCCCC1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.47
PGR P06401 2/20 0.47
NR3C2 P08235 1/20 0.47
CHRM2 P08172 8/20 0.38
CHRM1 P11229 8/20 0.38
CHRM3 P20309 7/20 0.38
CYP2D6 P10635 4/20 0.37
KCNH2 Q12809 4/20 0.37
CCR1 P32246 2/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
HRH1 P35367 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3658242 0.79 NR3C1 (0.56) NR3C1PGRNR3C2CHRM2CHRM1
SCHEMBL5388597 0.78 NR3C1 (0.45) NR3C1PGRNR3C2CHRM2CHRM1
SCHEMBL5384465 0.75 KEAP1 (0.45) CHRM2CHRM1CHRM3CYP2D6KCNH2
SCHEMBL5379197 0.73 NR3C1 (0.51) NR3C1PGRNR3C2CHRM2CHRM1
SCHEMBL7125970 0.70 NPC1 (0.44) OPRM1SIGMAR1
SCHEMBL4006317 0.70 KEAP1 (0.46) NR3C1PGRNR3C2CHRM2CHRM1
SCHEMBL13116345 0.69 KEAP1 (0.53) CHRM2CHRM1CHRM3KCNH2CCR1
SCHEMBL4618235 0.69 KEAP1 (0.53) CHRM2CHRM1CHRM3KCNH2CCR1
SCHEMBL4006253 0.68 KEAP1 (0.47) NR3C1PGRNR3C2CHRM2CHRM1
SCHEMBL5383863 0.68 TAAR1 (0.47) NR3C1PGRNR3C2CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238707-B2 Substituted pentanols, a process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2007-07-03 US disclosed
EP-1673344-A1 1-(QUINOLINE AMINO) AND 1-(ISOQUINOLINE AMINO)-SUBSTITUTED PENTAN-2-OLS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORIES Schering Aktiengesellschaft (DE) 2006-06-28 EP disclosed
US-20050143415-A1 Substituted pentanols, a process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2005-06-30 US disclosed
WO-2005035502-A1 1-(QUINOLINE AMINO) AND 1-(ISOQUINOLINE AMINO)-SUBSTITUTED PENTAN-2-OLS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORIES SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143415-A1 Substituted pentanols, a process for their production and their use as anti-inflammatory agents PTGES, TNF, PTGES2 NR3C1 458/4885PGR 2246/4885NR3C2 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.